Article Versions Notes

Zhou X, Jiao L, Qian Y, Dong Q, Sun Y, Zheng WV, Zhao W, Zhai W, Qiu L, Wu Y, et al. Repositioning Azelnidipine as a Dual Inhibitor Targeting CD47/SIRPα and TIGIT/PVR Pathways for Cancer Immuno-Therapy. Biomolecules. 2021; 11(5):706. https://doi.org/10.3390/biom11050706

Zhou, Xiuman, Ling Jiao, Yuzhen Qian, Qingyu Dong, Yixuan Sun, Wei V. Zheng, Wenshan Zhao, Wenjie Zhai, Lu Qiu, Yahong Wu, and et al. 2021. "Repositioning Azelnidipine as a Dual Inhibitor Targeting CD47/SIRPα and TIGIT/PVR Pathways for Cancer Immuno-Therapy" Biomolecules 11, no. 5: 706. https://doi.org/10.3390/biom11050706

Zhou, X., Jiao, L., Qian, Y., Dong, Q., Sun, Y., Zheng, W. V., Zhao, W., Zhai, W., Qiu, L., Wu, Y., Wang, H., Gao, Y., & Chen, J. (2021). Repositioning Azelnidipine as a Dual Inhibitor Targeting CD47/SIRPα and TIGIT/PVR Pathways for Cancer Immuno-Therapy. Biomolecules, 11(5), 706. https://doi.org/10.3390/biom11050706